Client News

Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care

CALGARY, Alberta and SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors … Continue reading “Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care”

By Optimum

ARIX Bioscience Plc Announces Board Changes, Appointment of Arthur Pappas to the Board of Directors, David U’Prichard to retire from Board

LONDON, 12 September 2018: Arix Bioscience plc (“Arix”) (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announced that industry veteran Arthur Pappas has been appointed … Continue reading “ARIX Bioscience Plc Announces Board Changes, Appointment of Arthur Pappas to the Board of Directors, David U’Prichard to retire from Board”

By Optimum

Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program

CALGARY, Alberta and SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors … Continue reading “Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program”

By Optimum

Azeria Therapeutics, the world’s first pioneer factor drug discovery company, announces Series A investment from Sixth Element Capital

Azeria Therapeutics Limited, a newly formed drug discovery company, today announced that it has successfully raised £4 million in Series A fundraising from the £70 million CRT Pioneer Fund, managed … Continue reading “Azeria Therapeutics, the world’s first pioneer factor drug discovery company, announces Series A investment from Sixth Element Capital”

By Optimum

Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer

Amsterdam, The Netherlands, August 30, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that Robbert van Heekeren is … Continue reading “Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer”

By Optimum

Silence Therapeutics Technology Licensee Quark Pharmaceuticals announces First Patient Dosed in Phase 3 Clinical Trial for Acute Kidney Injury

Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, … Continue reading “Silence Therapeutics Technology Licensee Quark Pharmaceuticals announces First Patient Dosed in Phase 3 Clinical Trial for Acute Kidney Injury”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH